Biohaven [BHVN] vs Zymeworks [ZYME] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Biohaven Ltd. wins in 3 metrics, Zymeworks Inc. wins in 11 metrics, with 0 ties. Zymeworks Inc. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Biohaven Ltd. | Zymeworks Inc. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | 3.79 | N/A |
| Price-to-Book Ratio | 26.84 | 7.32 | Zymeworks Inc. |
| Debt-to-Equity Ratio | 546.58 | 6.80 | Zymeworks Inc. |
| PEG Ratio | -5.26 | 0.05 | Zymeworks Inc. |
| EV/EBITDA | -2.22 | -20.40 | Biohaven Ltd. |
| Profit Margin (TTM) | 0.00% | -76.56% | Biohaven Ltd. |
| Operating Margin (TTM) | 0.00% | -1,755.55% | Biohaven Ltd. |
| Return on Equity | -310.75% | -26.72% | Zymeworks Inc. |
| Return on Assets (TTM) | -83.02% | -14.29% | Zymeworks Inc. |
| Free Cash Flow (TTM) | $-610.15M | $-35.36M | Zymeworks Inc. |
| 1-Year Return | -27.04% | 80.58% | Zymeworks Inc. |
| Price-to-Sales Ratio (TTM) | N/A | 18.46 | N/A |
| Enterprise Value | $1.55B | $1.73B | Zymeworks Inc. |
| EV/Revenue Ratio | N/A | 16.33 | N/A |
| Revenue per Share (TTM) | N/A | $1 | N/A |
| Earnings per Share (Diluted) | $-6.86 | $-1.08 | Zymeworks Inc. |
| Beta (Stock Volatility) | 3.62 | 1.20 | Zymeworks Inc. |
| Short % of Float | 20.25% | 8.16% | Zymeworks Inc. |
Biohaven Ltd. vs Zymeworks Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Biohaven Ltd. | 7.62% | 9.17% | 38.58% | 25.93% | 7.62% | 11.99% |
| Zymeworks Inc. | 1.66% | -2.80% | -2.80% | -1.52% | -10.44% | -12.62% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Biohaven Ltd. | -27.04% | -52.30% | 54.52% | -37.02% | -37.02% | -37.02% |
| Zymeworks Inc. | 80.58% | 181.77% | -36.88% | 76.00% | 76.00% | 76.00% |
Performance & Financial Health Analysis: Biohaven Ltd. vs Zymeworks Inc.
| Metric | BHVN | ZYME |
|---|---|---|
| Market Information | ||
| Market Cap | $1.49B | $1.96B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,841,635 | 626,460 |
| 90 Day Avg. Volume | 2,141,992 | 729,503 |
| Last Close | $12.14 | $23.26 |
| 52 Week Range | $7.48 - $18.57 | $11.51 - $29.75 |
| % from 52W High | -34.61% | -21.82% |
| All-Time High | $67.86 (Jun 03, 2019) | $59.03 (Jan 11, 2021) |
| % from All-Time High | -82.11% | -60.60% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | -0.92% |
| Quarterly Earnings Growth | N/A | -0.92% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | -0.77% |
| Operating Margin (TTM) | 0.00% | -17.56% |
| Return on Equity (TTM) | -3.11% | -0.27% |
| Debt to Equity (MRQ) | 546.58 | 6.80 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.39 | $3.60 |
| Cash per Share (MRQ) | $2.12 | $3.10 |
| Operating Cash Flow (TTM) | $-609,438,016 | $-33,005,000 |
| Levered Free Cash Flow (TTM) | $-358,118,432 | $-12,959,125 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Biohaven Ltd. vs Zymeworks Inc.
| Metric | BHVN (Apr 26, 2026) | ZYME (Apr 13, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | 3.79 |
| Forward P/E | -5.26 | 33.43 |
| PEG Ratio | -5.26 | 0.05 |
| Price to Sales (TTM) | N/A | 18.46 |
| Price to Book (MRQ) | 26.84 | 7.32 |
| Market Capitalization | ||
| Market Capitalization | $1.49B | $1.96B |
| Enterprise Value | $1.55B | $1.73B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 16.33 |
| Enterprise to EBITDA | -2.22 | -20.40 |
| Risk & Other Metrics | ||
| Beta | 3.62 | 1.20 |
| Book Value per Share (MRQ) | $0.39 | $3.60 |
Financial Statements Comparison: Biohaven Ltd. vs Zymeworks Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | BHVN (2025) | ZYME (2025) |
|---|---|---|
| Revenue/Sales | 0 | 105.97M |
| Cost of Goods Sold | N/A | N/A |
| COGS % of Revenue | - | 0.0% |
| Gross Profit | N/A | N/A |
| Gross Margin | - | 0.0% |
| Research & Development | 635.07M | 137.00M |
| Operating Income (EBIT) | -745.38M | -92.54M |
| Operating Margin | - | -87.3% |
| EBITDA | -735.46M | -80.82M |
| EBITDA Margin | - | -76.3% |
| Pre-Tax Income | -737.38M | -79.75M |
| Pre-Tax Income % of Revenue | - | -75.3% |
| Income Tax | 1.44M | 1.38M |
| Income Tax % of Revenue | - | 1.3% |
| Net Income (Profit) | -738.82M | -81.13M |
| Profit Margin | - | -76.6% |
Balance Sheet & Liquidity Metrics
| Metric | BHVN (2025) | ZYME (2025) |
|---|---|---|
| Cash & Equivalents | 229.96M | 41.16M |
| Total Current Assets | 368.33M | 248.77M |
| Total Current Assets % of Revenue | - | 234.8% |
| Total Current Liabilities | 115.93M | 42.32M |
| Total Current Liabilities % of Revenue | - | 39.9% |
| Long-Term Debt | 278.86M | 14.80M |
| Long-Term Debt % of Revenue | - | 14.0% |
| Total Shareholders Equity | 52.07M | 268.50M |
| Retained Earnings | -2.08B | -953.16M |
| Retained Earnings % of Revenue | - | -899.5% |
| Property, Plant & Equipment | 45.06M | 29.56M |
Cash Flow Statement Comparison
| Metric | BHVN (2025) | ZYME (2025) |
|---|---|---|
| Operating Cash Flow | -617.91M | -40.00M |
| Operating Cash Flow % of Revenue | - | -37.7% |
| Capital Expenditures | -715,000 | -1.52M |
| Free Cash Flow | -610.15M | -35.36M |
| FCF Margin | - | -33.4% |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | -41.70M |
Short Interest & Institutional Ownership Analysis
| Metric | BHVN | ZYME |
|---|---|---|
| Shares Short | 23.77M | 4.08M |
| Short Ratio | 9.21 | 5.42 |
| Short % of Float | 20.25% | 8.16% |
| Shares Outstanding | 132.78M | 75.19M |
| Float Shares | 123.86M | 72.80M |
| % Held by Insiders | 11.09% | 1.26% |
| % Held by Institutions | 91.64% | 98.45% |
| % Held by Public | -2.73% | 0.29% |
Dividend Analysis & Yield Comparison: Biohaven Ltd. vs Zymeworks Inc.
| Metric | BHVN | ZYME |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |